search_icon 

burgericon
Menü
close_icon

search_icon  

search_icon  

Publikationen

1. Colasante G, Qiu Y, Massimino L, Di Berardino C, Cornford JH, Snowball A, Weston M, Jones SP, Giannelli S, Lieb A, Schorge S, Kullmann DM, Broccoli V, Lignani G. In vivo CRISPRa decreases seizures and rescues cognitive deficits in a rodent model of epilepsy. Brain : a journal of neurology. 2020.

2. Lieb A*, Weston M*, Kullmann DM. Designer receptor technology for the treatment of epilepsy. EBioMedicine. 2019;43:641-9. *equal contribution

3. Magloire V, Cornford J, Lieb A, Kullmann DM, Pavlov I. KCC2 overexpression prevents the paradoxical seizure-promoting action of somatic inhibition. Nature communications. 2019;10(1):1225.

4. Salpietro V, Dixon CL, Guo H, Bello OD, Vandrovcova J, Efthymiou S, Maroofian R, Heimer G, Burglen L, Valence S, Torti E, Hacke M, Rankin J, Tariq H, Colin E, Procaccio V, Striano P, Mankad K, Lieb A, Chen S, Pisani L, Bettencourt C, Mannikko R, Manole A, Brusco A, Grosso E, Ferrero GB, Armstrong-Moron J, Gueden S, Bar-Yosef O, Tzadok M, Monaghan KG, Santiago-Sim T, Person RE, Cho MT, Willaert R, Yoo Y, Chae JH, Quan Y, Wu H, Wang T, Bernier RA, Xia K, Blesson A, Jain M, Motazacker MM, Jaeger B, Schneider AL, Boysen K, Muir AM, Myers CT, Gavrilova RH, Gunderson L, Schultz-Rogers L, Klee EW, Dyment D, Osmond M, Parellada M, Llorente C, Gonzalez-Penas J, Carracedo A, Van Haeringen A, Ruivenkamp C, Nava C, Heron D, Nardello R, Iacomino M, Minetti C, Skabar A, Fabretto A, Group SS, Raspall-Chaure M, Chez M, Tsai A, Fassi E, Shinawi M, Constantino JN, De Zorzi R, Fortuna S, Kok F, Keren B, Bonneau D, Choi M, Benzeev B, Zara F, Mefford HC, Scheffer IE, Clayton-Smith J, Macaya A, Rothman JE, Eichler EE, Kullmann DM, Houlden H. AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders. Nature communications. 2019;10(1):3094.

5. Shekh-Ahmad T, Lieb A, Kovac S, Gola L, Wigley CW, Abramov AY, Walker MC. Combination antioxidant therapy prevents epileptogenesis and modifies chronic epilepsy. Redox Biology. 2019:101278.

6. Snowball A, Chabrol E, Wykes RC, Shekh-Ahmad T, Cornford JH, Lieb A, Hughes MP, Massaro G, Rahim AA, Hashemi KS, Kullmann DM, Walker MC, Schorge S. Epilepsy gene therapy using an engineered potassium channel. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2019.

7. Weston M, Kaserer T, Wu A, Mouravlev A, Carpenter JC, Snowball A, Knauss S, von Schimmelmann M, During MJ, Lignani G, Schorge S, Young D, Kullmann DM, Lieb A. Olanzapine: A potent agonist at the hM4D(Gi) DREADD amenable to clinical translation of chemogenetics. Sci Adv. 2019;5(4):eaaw1567.

8. Chang BL, Leite M, Snowball A, Lieb A, Chabrol E, Walker MC, Kullmann DM, Schorge S, Wykes RC. Semiology, clustering, periodicity and natural history of seizures in an experimental occipital cortical epilepsy model. Dis Model Mech. 2018;11(12).

9. Lieb A#, Qiu Y, Dixon CL, Heller JP, Walker MC, Schorge S, Kullmann DM. Biochemical autoregulatory gene therapy for focal epilepsy. Nature medicine. 2018;24(9):1324-9. #corresponding author

10. Pinggera A, Negro G, Tuluc P, Brown MJ, Lieb A, Striessnig J. Gating defects of disease-causing de novo mutations in Cav1.3 Ca(2+) channels. Channels. 2018;12(1):388-402.

11. Monteleone S, Lieb A, Pinggera A, Negro G, Fuchs JE, Hofer F, Striessnig J, Tuluc P, Liedl KR. Mechanisms Responsible for omega-Pore Currents in Cav Calcium Channel Voltage-Sensing Domains. Biophys J. 2017;113(7):1485-95.

12. Kaur G, Pinggera A, Ortner NJ, Lieb A, Sinnegger-Brauns MJ, Yarov-Yarovoy V, Obermair GJ, Flucher BE, Striessnig J. A Polybasic Plasma Membrane Binding Motif in the I-II Linker Stabilizes Voltage-gated CaV1.2 Calcium Channel Function. The Journal of biological chemistry. 2015;290(34):21086-100.

13. Pinggera A*, Lieb A*, Benedetti B, Lampert M, Monteleone S, Liedl KR, Tuluc P, Striessnig J. CACNA1D de novo mutations in autism spectrum disorders activate Cav1.3 L-type calcium channels. Biol Psychiatry. 2015;77(9):816-22. *equal contribution

14. Scharinger A, Eckrich S, Vandael DH, Schonig K, Koschak A, Hecker D, Kaur G, Lee A, Sah A, Bartsch D, Benedetti B, Lieb A, Schick B, Singewald N, Sinnegger-Brauns MJ, Carbone E, Engel J, Striessnig J. Cell-type-specific tuning of Cav1.3 Ca(2+)-channels by a C-terminal automodulatory domain. Frontiers in cellular neuroscience. 2015;9:309.

15. Lieb A#, Ortner N, Striessnig J. C-terminal modulatory domain controls coupling of voltage-sensing to pore opening in Cav1.3 L-type Ca(2+) channels. Biophys J. 2014;106(7):1467-75. #corresponding author

16. Azizan EA, Poulsen H, Tuluc P, Zhou J, Clausen MV, Lieb A, Maniero C, Garg S, Bochukova EG, Zhao W, Shaikh LH, Brighton CA, Teo AE, Davenport AP, Dekkers T, Tops B, Kusters B, Ceral J, Yeo GS, Neogi SG, McFarlane I, Rosenfeld N, Marass F, Hadfield J, Margas W, Chaggar K, Solar M, Deinum J, Dolphin AC, Farooqi IS, Striessnig J, Nissen P, Brown MJ. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet. 2013;45(9):1055-60.

17. Lieb A, Scharinger A, Sartori S, Sinnegger-Brauns MJ, Striessnig J. Structural determinants of CaV1.3 L-type calcium channel gating. Channels. 2012;6(3):197-205.

18. Baig SM, Koschak A, Lieb A, Gebhart M, Dafinger C, Nurnberg G, Ali A, Ahmad I, Sinnegger-Brauns MJ, Brandt N, Engel J, Mangoni ME, Farooq M, Khan HU, Nurnberg P, Striessnig J, Bolz HJ. Loss of Ca(v)1.3 (CACNA1D) function in a human channelopathy with bradycardia and congenital deafness. Nature neuroscience. 2011;14(1):77-84. 19. Hornick A*, Lieb A*, Vo NP, Rollinger JM, Stuppner H, Prast H. The coumarin scopoletin potentiates acetylcholine release from synaptosomes, amplifies hippocampal long-term potentiation and ameliorates anticholinergic- and age-impaired memory. Neuroscience. 2011;197:280-92. *equal contribution

 

 

 

Forschung